European Journal of Epidemiology

, Volume 19, Issue 3, pp 225–230 | Cite as

Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients

  • Lotus Mallbris
  • Olof Akre
  • Fredrik Granath
  • Li Yin
  • Bernt Lindelöf
  • Anders Ekbom
  • Mona Ståhle-Bäckdahl


We have conducted a historical cohort study to assess cardiovascular mortality among psoriasis patients. Using the Swedish Inpatient Registry, we selected 8991 patients hospitalized for psoriasis at dermatological wards. To represent an outpatient cohort, 19,757 members of the Swedish Psoriasis Association were selected. Mortality from cardiovascular diseases was compared with the general population. We found no increased cardiovascular mortality among outpatients with psoriasis (standardized mortality ratio, SMR 0.94; 95% confidence interval, CI: 0.89–0.99). The overall risk among inpatients admitted at least once was increased by 50%(SMR 1.52; 95% CI: 1.44–1.60). The excess risk increased with increasing number of hospital admissions (p for trend <0.001). Cardiovascular mortality was higher among those admitted at younger ages (p for trend <0.001; SMR 2.62, 95% CI: 1.91–3.49, for patients aged 20 to 39 years at first admission). Young age at first admission appeared to further increase the risk among those who were repeatedly admitted. We conclude that a diagnosis of psoriasis per se does not appear to increase the risk for cardiovascular mortality. Severe psoriasis, however, here measured as repeated admissions, and early age at first admission, is associated with increased risk for cardiovascular death.

Atherosclerosis Cardiovascular death Epidemiology Inflammation Psoriasis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henseler T, Christophers E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.Google Scholar
  2. 2.
    McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99: 469-475.Google Scholar
  3. 3.
    Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.Google Scholar
  4. 4.
    Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospitaltreated patients with psoriasis. Arch Dermatol 1999; 135: 1490-1493.Google Scholar
  5. 5.
    Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1380 patients. J Invest Dermatol 1988; 91: 197-201.Google Scholar
  6. 6.
    Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.Google Scholar
  7. 7.
    Seckin D, Tokgozoglu L, Akkaya S. Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 1994; 31(3 Pt 1): 445-449.Google Scholar
  8. 8.
    Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256: 2540-2544.Google Scholar
  9. 9.
    Grossman RM, Delaney RJ, Brinton EA, Carter DM, Gottlieb AB. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 1991; 25: 648-651.Google Scholar
  10. 10.
    Izaki S, Yamamoto T, Goto Y. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Br J Dermatol 1996; 134: 1060-1064.Google Scholar
  11. 11.
    Ludwig RJ. Platelet activation in psoriasis: A possible link to skin inflammation. J Invest Dermatol 2001; 117: 766.Google Scholar
  12. 12.
    Mallet AI, Cunningham FM. Structural identification of platelet activating factor in psoriatic scale. Biochem Biophys Res Commun 1985; 126: 192-198.Google Scholar
  13. 13.
    Judge MR, Barr RM, Mallet AI, Courtney F, Kobza Black A, Greaves MW. Platelet activating factor (PAF) and lyso-PAF in psoriasis. Arch Dermatol Res 1994; 286: 376-379.Google Scholar
  14. 14.
    Dentan C, Lesnik P, Chapman MJ, Ninio E. Phagocytic activation induces formation of platelet-activating factor in human monocyte-derived macrophages and in macrophage-derived foam cells. Relevance to the in-flammatory reaction in atherogenesis. Eur J Biochem 1996; 236: 48-55.Google Scholar
  15. 15.
    Brocheriou I, Stengel D, Mattsson-Hulten L., et al. Expression of platelet-activating factor receptor in human carotid atherosclerotic plaques: Relevance to progression of atherosclerosis. Circulation 2000; 102: 2569-2575.Google Scholar
  16. 16.
    Naessen T, Parker R, Persson I, Zack M, Adami HO. Time trends in incidence rates of first hip fracture in the Uppsala Health Care Region, Sweden, 1965-1983. Am J Epidemiol 1989; 130: 289-299.Google Scholar
  17. 17.
    Welfare NB. Cause of death 1997. Stockholm. 2000.Google Scholar
  18. 18.
    Fischer T. Psoriasis outpatient care centers: The Swedish model. Semin Dermatol 1985; 4: 293-295.Google Scholar
  19. 19.
    Lindelof B, Eklund G, Liden S, Stern RS. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990; 22(6 Pt 1): 1056-1060.Google Scholar
  20. 20.
    Breslow NE. The design and analysis of cohort studies. Statistical methods in cancer research. Vol. II. Lyon: IARC Sci. Publ., 1987: 1-406.Google Scholar
  21. 21.
    Inc SI. SAS/STAT® Software. Changes and enhancements through release 6.12. Cary, NC: SAS Institute, 1997: 247-348.Google Scholar
  22. 22.
    Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994; 130: 473-477.Google Scholar
  23. 23.
    Naldi L, Parazzini F, Brevi A, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol 1992; 127: 212-217.Google Scholar
  24. 24.
    Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-1893.Google Scholar
  25. 25.
    Hanahan DJ. Platelet activating factor: A biologically active phosphoglyceride. Annu Rev Biochem 1986; 55: 483-509.Google Scholar
  26. 26.
    Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30(5 Suppl): S294-S301.Google Scholar
  27. 27.
    Zhang Y, Gu Y, Lucas MJ, Wang Y. Antioxidant superoxide dismutase attenuates increased endothelial permeability induced by platelet-activating factor. J Soc Gynecol Investig 2003; 10: 5-10.Google Scholar
  28. 28.
    Subbanagounder G, Leitinger N, Shih PT, Faull KF, Berliner JA. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: In vitro and in vivo inhibition by WEB 2086. Circ Res 1999; 85: 311-318.Google Scholar
  29. 29.
    Mueller HW, Haught CA, McNatt JM, et al. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res 1995; 77: 54-63.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Lotus Mallbris
    • 1
  • Olof Akre
    • 2
  • Fredrik Granath
    • 2
  • Li Yin
    • 2
  • Bernt Lindelöf
    • 2
  • Anders Ekbom
    • 2
  • Mona Ståhle-Bäckdahl
    • 2
  1. 1.Dermatology UnitKarolinska HospitalStockholmSweden
  2. 2.Clinical Epidemiology Unit, Department of MedicineKarolinska InstituteStockholmSweden

Personalised recommendations